Send comments to Susan G. Queen, Ph.D., HRSA Reports Clearance Officer, Room 14–45, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: November 19, 2003.

Tina M. Cheatham,

Acting Director, Division of Policy Review and Coordination.

[FR Doc. 03–29466 Filed 11–25–03; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Geldanamycin Derivatives With Methyl Substituted Hydrogen Atom at the N22 Position as Anti Cancer Agents

Yong-Sok Lee, Leonard Neckers, Monica Marcu (NCI).

U.S. Provisional Patent Application No. 60/508,752 filed 03 Oct 2003 (DHHS Reference Nos. E–169–2003/0–US–01).

Licensing Contact: George Pipia; 301/435–5560; pipiag@mail.nih.gov.

This invention is directed to an N22-methyl substituted derivatives of geldanamycin. Modeling studies have shown that providing a methyl substituent in the N22 position of geldanamycin derivatives stabilizes the cis-conformation of the compounds. From computer modeling and

mutational studies inventors concluded that the active form of geldanamycin interacting with heat shock protein 90 (Hsp90) has the amid bond in cisconfiguration, which is energetically less stable than in trans-configuration. Using computer-modeling investigators have further demonstrated that methyl substitution at the N22 position of geldanamycin stabilizes the cisderivatives of geldanamycin. These compounds are currently being synthesized at NCI. These compounds are expected to have an increased binding to and inhibition of Hsp90. Inhibition of Hsp90 is being investigated in the treatment of many cancers.

Degradation and Transcriptional Inhibition of HIF-2alpha Protein by 17– AAG

Jennifer Isaacs, Leonard Neckers (NCI).

U.S. Provisional Patent Application No. 60/508,795 filed 03 Oct 2003 (DHHS Reference No. E–064–2003/0–US–01).

Licensing Contact: George Pipia; 301/435–5560; pipiag@mail.nih.gov.

The technology is directed to the use of 17-allylaminogeldanamycin (17-AAG) and, by analogy, other geldanamycin derivatives to inhibit the activity of hypoxia inducible factor-2a (HIF-2a). HIF-2a is thought to play an important role in tumor growth in the lung and endothelium, and is overexpressed in a majority of renal carcinomas. Accordingly, the technology suggests the use of 17-AAG and other geldanamycin derivatives to reduce levels of HIF-2a in cells that overexpress the protein, for example to treat cancer. According to the lead inventor, HIF-2a plays a central role behind the mechanism of action of geldanamycin in renal cancer. The inventors also predict that certain geldanamycin derivatives will have therapeutic benefit in tumors overexpressing HIF-2a, and that those derivatives could also find therapeutic utility in clinical conditions involving hypervascularization.

 $Dated: November\ 13,\ 2003.$

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 03–29492 Filed 11–25–03; 8:45~am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis Panel.

Date: December 9, 2003.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Crystal City, 2399 Jefferson Davis Hwy., Arlington, VA 22202.

Contact Person: Jeanette M Hosseini, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, Bethesda, MD 20892, (301) 451–2020.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: November 19, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–29478 Filed 11–25–03; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contract Person listed below in advance of the meeting.

Name of Committee: National Children's Study Advisory Committee.